Arellano et al. Revumenib for Patients With Relapsed or Refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Updated Results From the Phase 2 AUGMENT-101 Study. Presented at the 30th Annual Congress of the European Hematology Association; 12–15 June 2025; Milan, Italy.